News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Innate Pharma Updates on its Next Meetings with Analysts and Investors

3/23/2011 2:18:48 PM

Marseilles, France, March 23, 2011 -- Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that it will participate to the following analyst and investor conferences in the coming weeks:

- Benelux Midcap Event in Brussels, Belgium, on March 31 & April 1, 2011

- Paris Smallcap Event in Paris, France, on April 26 & 27, 2011

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company’s website (www.innate- and contact the investor relations team by writing to investors@innate-

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting regulation pathways of innate immunity cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal antibody potentiating NK cells activation currently in Phase II clinical trials in hematologic cancers. Two of its antibody programs in chronic inflammation are out- licensed to Novo Nordisk A/S.

Innate Pharma’s key expertise is in immunopharmacology and antibody technology. The Company has implemented in-house a large panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In addition, Innate Pharma has access to a very large set of unique research tools in cellular immunology through its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 86 employees as at December 31, 2010.

Learn more about Innate Pharma at

Practical Information about Innate Pharma shares:

ISIN code Ticker code FR0010331421 IPH

Disclaimer: This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma Alize Public Relations Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87

Alize Public Relations Caroline Carmagnol Phone: +33 (0)1 41 22 07 31 Mobile: +33 (0)6 64 18 99 59

Read at

comments powered by Disqus